RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers
2017 Salaries and Bonus Targets. On March14, 2017, the
Compensation Committee of the Board of Directors of RTI Surgical,
Inc. (the Company) approved 2017 salaries and bonus targets
(expressed as a percentage of salary) for each of the Companys
executive officers. The table below sets forth this information:
|
Name |
Office |
2017 Salary | Bonus Target | |||||||
|
Camille Farhat |
President and Chief Executive Officer |
$ | 635,000 | % | ||||||
|
Robert P. Jordheim |
Executive Vice President and Chief Financial Officer |
$ | 374,286 | % | ||||||
|
Roger W. Rose |
President, RTI Donor Services, Executive Vice President |
$ | 350,115 | % | ||||||
|
Kevin D. Brandt |
Executive Vice President, Chief Commercial Officer Domestic |
$ | 337,366 | % | ||||||
|
John N. Varela |
Executive Vice President Global Operations |
$ | 337,428 | % |
At a subsequent meeting, the Compensation Committee will set the
cash bonus performance criteria for each of the Companys
executive officers and also approve equity awards to certain
executive officers to the 2015 Incentive Compensation Plan. At
such time, the Company will file an amendment to this Current
Report on Form 8-K
to disclose such information.
About RTI SURGICAL, INC. (NASDAQ:RTIX)
RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world. RTI SURGICAL, INC. (NASDAQ:RTIX) Recent Trading Information
RTI SURGICAL, INC. (NASDAQ:RTIX) closed its last trading session down -0.11 at 3.74 with 370,111 shares trading hands.
